- Core B The Pathology and High Resolution Imaging Core is an effective nucleus that supports the various studies of the P01 by providing well-characterized, and highly annotated archival pathological samples collected from different prostate cancer (PC) cell lines, human and animal model experimental tissue and by performing routine and advanced histological procedures on soft and hard tissues. The Core also provides clinical diagnostic evaluation of histological sections and immunohistochemical interpretation of human and murine prostatic tissue and PC bone metastases. P01 investigators utilizing animal necropsies also have access to sophisticated techniques, such as transmission electron microscopy, image analysis/morphometry and laser microdissection. Techniques available include histology (special stains, frozen, paraffin- and plastic-embedded sections) and immunohistochemistry. A key advantage of the Core is that it is embedded within the Center for Metabolic Bone Disease at the University of Alabama at Birmingham and works in close partnership with the Biobank and Translational Research Core at Cedars-Sinai Medical Center (CSMC) and with the West Los Angeles VA Medical Center. This partnership provides the Core with a unique position to serve the research needs of P01 investigators in their studies of the molecular and cellular mechanisms of PC bone metastasis, including: a) procurement of fresh prostatic and bone metastatic tissue: primary tumor, tumor-related stroma, benign epithelium, metastatic bone specimens, and stroma unrelated to tumor from clinical specimens under direct morphologic visualization using laser capture microscopy for molecular analyses; b) service as the morphology core, providing PC diagnostic expertise for both clinical specimens and animal models, frozen section and light microscopic facilities, histochemistry, immunohistochemistry, in situ hybridization and quantitative histomorphometry; and c) providing well-characterized, archived pathologic samples and tissue microarrays (TMAs) for screening of candidate molecules of potential mechanistic importance, validation of cell culture and animal model experimental data and discovery of novel biomarkers, including high throughput analysis. The ongoing development of centrally performed procedures frees the P01 investigators from duplication of basic work, allowing them greater productivity with available resources and acceleration of experimental timetables. It also allows comparison of results between investigators with assurance that technical preparatory conditions are not responsible for observed differences. In summary, Core B will continue to provide the P01 with routine and advanced technical preparations and expert interpretation of both diagnostic and molecular analysis of cell and tissue samples from humans and animals. The standardization of the quality-controlled procedures will ultimately lead to greater technical uniformity and allow for direct comparisons of data between projects.
- Core B The mission of the Pathology and High Resolution imaging core is to provide the P01 with state-of-the-art instrumentation, expertise and standardized routine and advanced histological and imaging services in order to assist project investigators with the validation of their hypotheses. Furthermore, the Core will be procuring fresh prostatic and bone metastatic tissue and provide prostate cancer diagnostic expertise for both clinical specimens and animal models of prostate cancer.
|Farach-Carson, Mary C; Lin, Sue-Hwa; Nalty, Theresa et al. (2017) Sex Differences and Bone Metastases of Breast, Lung, and Prostate Cancers: Do Bone Homing Cancers Favor Feminized Bone Marrow? Front Oncol 7:163|
|Stewart, Paul A; Khamis, Zahraa I; Zhau, Haiyen E et al. (2017) Upregulation of minichromosome maintenance complex component 3 during epithelial-to-mesenchymal transition in human prostate cancer. Oncotarget 8:39209-39217|
|Masko, Elizabeth M; Alfaqih, Mahmoud A; Solomon, Keith R et al. (2017) Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model. Prostate 77:446-457|
|Jolly, Mohit Kumar; Boareto, Marcelo; Debeb, Bisrat G et al. (2017) Inflammatory breast cancer: a model for investigating cluster-based dissemination. NPJ Breast Cancer 3:21|
|Alfaqih, Mahmoud A; Allott, Emma H; Hamilton, Robert J et al. (2017) The current evidence on statin use and prostate cancer prevention: are we there yet? Nat Rev Urol 14:107-119|
|Guan, Yang; Zhang, Yi; Xiao, Li et al. (2017) Improving Therapeutic Potential of Farnesylthiosalicylic Acid: Tumor Specific Delivery via Conjugation with Heptamethine Cyanine Dye. Mol Pharm 14:1-13|
|Nandana, Srinivas; Tripathi, Manisha; Duan, Peng et al. (2017) Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis. Cancer Res 77:1331-1344|
|Brennen, W Nathaniel; Zhang, Baohui; Kulac, Ibrahim et al. (2017) Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. Oncotarget 8:46710-46727|
|Tighiouart, Mourad; Cook-Wiens, Galen; Rogatko, André (2017) A Bayesian adaptive design for cancer phase I trials using a flexible range of doses. J Biopharm Stat :1-13|
|Tighiouart, Mourad; Li, Quanlin; Rogatko, André (2017) A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials. Stat Med 36:280-290|
Showing the most recent 10 out of 208 publications